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Abstract: The aim of this study was to assess the diagnostic value of vaginal insulin-like growth factor binding protein-1 (IGFBP-I)
in the detection of amniotic fluid leakage after amniocentesis.
It includes 58 healthy pregnant women who successfully underwent amniocentesis at 15-20 weeks of gestation. After amniocentesis
patients were evaluated for amniotic fluid leakage at 60 min, 48 h, and 6 weeks after the procedure with speculum examination,
nitrazine paper test and microscopic evidence of ferning, and were grouped into Group I (at least 2 positive tests) and Group II
(others) according to the first evaluation. All patients tested for vaginal IGFBP-I.
A total of 1.1% (7/58) of patients met the Group I criteria. Vaginal bleeding and contraction occurrence was nonsignificantly higher
in Group I. One false positive and one false negative result were obtained from IGFBP-I testing. The sensitivity of this test was 85%,
specificity was 98%, positive predictive value (PPV) was 85% and negative predictive value (NPV) was 98%. After 48 h the
sensitivity of this test was 75%, specificity was 98%, PPV was 75% and NPV was 98%. Results at the 6th week were similar to
those at 48 h.
In conclusion the detection of vaginal IGFBP-I is highly predictive for amniotic fluid leakage especially in clinically doubtful cases.
Key Words: Amniocentesis, amniotic leakage, insulin-like growth factor binding protein–I (IGFBP-I)
Abbreviations: PROM: Premature rupture of membranes, IGFBP-I: Insulin-like growth factor binding protein-1,
PPV: Positive predictive value, NPV: Negative predictive value

Introduction
Genetic amniocentesis is one of the most widely
utilized prenatal diagnostic techniques. It presently allows
the detection of chromosome abnormalities, inborn
errors of metabolism, hemoglobinopathies and other
biochemical disorders. However, it is also associated with
some maternal and fetal complications. In the literature,
vaginal leakage of amniotic fluid after amniocentesis has
been reported (1).
Chronic leakage of amniotic fluid or premature
rupture of membranes (PROM) is associated with
increased infectious morbidity for the mother and the
fetus (2,3). In the majority of cases the diagnosis is

confirmed after ascertaining the history of the patient
and performing a detailed pelvic examination. However,
the leakage of the amniotic fluid may be intermittant and
there may be no fluid collection in the vagina, or the
vaginal fluid may be contaminated with urine, semen or
other secretions.
Many different tests have been developed to diagnose
rupture of the fetal membranes (4). However, most of
the tests lack the necessary sensitivity and specificity to
diagnose PROM, especially in doubtful conditions.
A false positive diagnosis of PROM may lead to
inappropriate intervention, and a false negative diagnosis
may result in an increased risk of maternal and fetal
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morbidity. The absence of a noninvasive gold standard for
the diagnosis of membrane rupture has led to the search
for alternative biochemical markers vaginal prolactin, αfeto protein, fetal fibronectin a etc. have previously been
studied (5,6).
Insulin-like growth factor binding protein-I(IGFBP–I)
detection has been promoted as a reliable and ideal
marker to diagnose ruptured fetal membranes or
amniotic fluid leakage (7-9). May initial study by Rutanen
et al. reported that membrane rupture was associated
with detectable IGFBP-I in vaginal secretions. IGFBP-I is a
major protein in amniotic fluid and its average
concentrations are ≥ 400-fold higher than those in
maternal serum (4).
This study was conducted to assess the diagnostic
value of vaginal IGFBP-I in the detection of amniotic fluid
leakage after amniocentesis.

Materials and Methods
This prospective study was carried out on 58 healthy
pregnant women, recruited from parturients admitted to
the perinatology department of the Zekai Tahir Burak
Women’s Health Education and Research Hospital.
Genetic amniocentesis was performed successfully in all
cases at 15–20 weeks of gestation. The indications
considered for amniocentesis were as follows: advanced
maternal age, a previous child with a chromosome or
structural abnormality or positive family history, positive
family history for neural tube defects, previous history of
recurrent miscarriages and stillbirths, parents carriers of
an autosomal recessive disorder diagnosable in utero and
abnormal maternal serum screening results.
Exclusion criteria from the study included vaginal
bleeding, uterine contractions,and the presence of any
prenatal complications or multiple pregnancy.
On admission, age, parity and gestational age were
registered at the time of initial evaluation. Total blood
count, Rh blood type tests, physical examination and
ultrasonographic evaluation were performed. The
advantages and risks of the invasive procedure and
information about the study were explained to all the
subjects. All participants and their husbands gave their
written informed consent. After ultrasonographic
examination was performed to localize the placenta and
fetus and to re-evaluate the gestastional age
approximately 15–20 cc of amniotic fluid is removed
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transabdominally under sterile conditions using a 20
gauge needle.
Speculum examination was performed 60 min after
the procedure. At speculum examination, vaginal pooling
of fluid was registered. Nitrazine paper test and
microscopic evaluation of ferning on a dried vaginal
smear were performed. Patients were diagnosed as
having membrane rupture if they demonstrated at least 2
of the following indices: vaginal pooling of fluid, a positive
nitrazine paper test, or microscopic evidence of ferning
and positive IGFBP-I testing. The actim PROM test,
(Medix Biochemical OY AB, Kauniainen, Finland), was
used to determine IGFBP–I in vaginal specimens. An actim
PROM test was performed by obtaining a sample of
vaginal secretion using a Dacron swab placed in the
posterior fornix or in the cervical canal for 10 s. The
swab was rinsed in a buffer tube and a dipstick was
placed in the tube for approximately 20 s. The stick
countains monoclonal antibodies to IGFBP-I and absorbs
the extracted specimen. If the amniotic fluid contains >25
mg/l of IGFBP–I, in the extracted sample 2 blue lines will
appear on the stick.
The subjects were then classified as follows: amniotic
fluid leakage (+) cases were classified as Group I and
amniotic fluid leakage (-) cases as Group II, according to
the test results. All subjects underwent ultrasonographic
examination to evaluate fetal well-being and amniotic
fluid indices. All the examinations were performed by the
same physician in order to eliminate interobserver
sampling differences. The subjects were then re-evaluate
at 48 h and at 6 weeks in terms of amniotic fluid leakage
and fetal well-being.
All data were analyzed using SPSS-PC (version 11.0).
For statistical analysis, Student’s t test, Mann–Whitney U
test and Fisher’s exact test were used. Sensitivity,
specificity, positive predictive values (PPVs) and negative
predictive values (NPVs) of the IGFBP-I test were then
calculated.
Results
Demographic characteristics of the subjects are shown
in Table 1. Mean maternal age was 31.5, ranging from
18 to 43. Mean gestational age of all subjects at time of
amniocentesis was 18.51 weeks (16 – 21 weeks). There
were no significant differences between the 2 groups
with regard to maternal age, parity or gestational age
(Table 1).
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Table 1. Demographic characteristics of the subjects.
Characteristics

Group I
(n=7)

Group II
(n= 51)

P

29 ± 5.6

28 ± 4.8

>0.05x

Parity

1.01 ± 0.9

0.98 ± 0.8

>0.05x

Gestational age (weeks)

18.8 ± 4.1

18.4 ± 3.6

>0.05x

Occurrence of contractions (> 4 per hour)

1/7 (14%)

4/51 (8%)

>0.05y

Vaginal bleeding

I/7 (14%)

5/51 (10%)

>0.05y

Age (years)

Values are expressed as mean ± S.D. or number / percentages
X = Student’s t test
Y = Fisher’s exact test

Of the 56 subjects, 1.1% (6/56) of cases met the
criteria for transient amniotic fluid leakage. The
incidences of patients with vaginal bleeding and
occurrence of contractions were higher in actim PROM
test (+) cases than the in actim PROM (-) group.
However, there were no statistically significant
differences between the 2 groups with regard to these
parameters. No signs of chorioamnionitis were detected
in any of the patients. Only one patient from the amniotic
fluid leakage (+) group delivered within 4 weeks after
sampling. In this patient an obstetrical history of
gestational diabetes in her previous pregnancy was
recorded (Table 2).
One false positive and one false negative case were
observed during the course of the study. The false
positive case occurred in a patient admitted to the
hospital at 21 weeks of gestation, at a later period in
comparison with the other cases. The vaginal sample
obtained from this woman was grossly contaminated
with maternal blood, which can easily alter the result.
However the false negative result detected in the other
case may be attributed to inadequate sampling.

Table 2. Diagnostic values of IGFBP-I levels (just after amniocentesis).
Actim PROM
test (+)
Group I

Actim PROM
test (-)

The sensitivity of the actim PROM test compared to
that of other commercial tests and clinical evaluation was
recorded as 85% just after the procedure. The rate of
specificity was 98%, PPV was 85% and NPV was 98%.
Diagnostic values of IGFBP-I levels and the rate of
amniotic fluid leakage at 48 h after the procedure are
shown in Table 3. The rate of amniotic fluid leakage was
0.68% at 48 h.
The sensitivity of the actim PROM test compared to
that of other commercial tests and clinical evaluation was
recorded as 75% at 48 h after the procedure. The rate
of specificity was 98%; PPV was 75% and NPV was
98%.
The diagnostic values of IGFBP-I with chromic
amniotic fluid leakage during a check-up which
performed after 6 weeks were similar to those at 48 h.
Although the incidence of chronic amniotic fluid
leakage was recorded as 0.68%, neither pathology in
fetal condition nor a decrease in amniotic fluid value were
observed either at 48 h or 6 weeks.

Table 3. Diagnostic values of IGFBP-I levels (at 48 h after procedure).

Total

Actim PROM
test (+)

Actim PROM
test (-)

Total

(n = 7)

6

I

7

Group I

(n = 7)

3

I

4

Group II (n = 51)

I

50

51

Group II (n = 51)

I

53

54

Total

7

51

58

Total

4

54

58

Sensitivity 85%; Specificity 98%; PPV 85%; NPV 98%

Sensitivity 75%; Specifity 98%; PPV 75%; NPV 98%

159

Insulin-Like Growth Factor Binding Protein-I; a Rapid Detection of Amniotic Fluid Leakage after Amniocentesis

Discussion
Amniocentesis is one the most widely used techniques
in prenatal diagnosis. However it has also some maternal
and fetal risks. Amniotic fluid leakage has been suggested
as a possible cause of increased fetal and maternal
morbidity (10,11). Tabor et al. reported a controlled trial
of genetic amniocentesis in 4606 women (1). In this
study amniotic fluid leakage occurred more commonly in
the study group than in the control group (1.7% vs
0.4%). Amniotic fluid leakage was recorded in 1.1% of
cases, consistent with the results of earlier studies in the
literature.
As chronic leakage of amniotic fluid is associated with
increased morbidity for the mother and the fetus, failure
of diagnosis can lead to unwanted obstetric
complications. If the diagnosis of amniotic fluid leakage
remains uncertain using physical examination or
commercial methods, the ideal method for demonstrating
the presence of amniotic fluid in the vagina should be
rapid and have high accuracy. Transient vaginal amniotic
fluid leakage is also common after genetic amniocentesis.
However, even occult rupture of fetal membranes may
indicate an increased risk of preterm delivery, abortion,
fetal loss and/or intrauterine infection.
Since there is no gold standard test applicable to all
subjects with high accuracy, many different biochemical
markers have previously been studied like fetal
fibronectin, α-feto protein, prolactin and diaminoxidase
(11).
Most tests diagnosing amniotic fluid leakage have
limited sensitivity and specificity due to confounding
factors like vaginal discharge, maternal blood loss, and
cross reactions with urine or cervical mucus. A low
gradient between serum and amniotic fluid has also
limited the diagnostic value of some biochemical markers.
Moreover, some previously used tests to detect amniotic
fluid in the vagina are based on radioimmunoassay
techniques, with a possible delay of the result of up to 24
h. In patients with clinically doubtful ruptured fetal
membranes, this limited sensitivity and specificity become
particularly apparent.
IGFBP-I detection can be easily used for the diagnosis
of amniotic fluid leakage or ruptured fetal membranes in
obstetrical practice. Although the precise source of
amniotic IGFBP-I remains uncertain, it has been
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immunohistochemically localized to the decidua, but only
weak staining was observed in the amniochorionic layer.
The marked gradient between blood and amniotic fluid
IGFBP-I concentrations makes IGFBP-I a potential marker
for the detection of amniotic fluid leakage or ruptured
fetal membranes.
In the literature, several studies have indicated that
IGFBP-I detection showed high sensitivity (91%–100%),
specificity (83%–95%) and PPV (85%–95%) even in
cases in which the diagnosis is clinically doubtful(12). In
our series, it was observed that IGFBP-I detection showed
a high sensitivity rate of 85%, specificity of 98%, PPV of
85% and NPV of 98%, in agreement with previous
studies.
Different factors may interfere with the predictive
values of IGFBP-I detection. In this study there were one
false positive and one false negative case. Several reports
have indicated that false positive results may be caused by
contamination with grossly bloody vaginal discharge.
False negative results may be caused by inadequate
sampling, intra-amniotic infections or proteolytic
degradation of IGFBP-I in the vagina. However Rutanen
et al. reported that bloody and other secretions that may
contaminate amniotic fluid in the vagina did not appear to
interfere with the test results (4). In this study while the
false positive vaginal IGFBP-I result was likely to be
related to the presence of contamination of maternal
blood, the false negative case may have been related to
inadequate sampling technique.
In conclusion, the detection of vaginal IGFBP-I is
highly predictive of amniotic fluid leakage or ruptured
fetal membranes, especially in clinically doubtfull cases.
The rest is easily performed in the clinical set up and no
analytical difference has been reported in the IGFBP-I
assay. However, because of the possible interference with
other factors, IGFBP-1 detection has been suggested as a
useful complement to other tests, to confirm an accurate
diagnosis of amniotic fluid leakage.
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